



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Hematology,
a section of the journal
Frontiers in Medicine

RECEIVED 14 March 2023
ACCEPTED 14 March 2023
PUBLISHED 27 March 2023

CITATION
Frontiers Production Office (2023) Erratum:
Immune-mediated thrombotic
thrombocytopenic purpura following
mRNA-based COVID-19 vaccine BNT162b2:
Case report and mini-review of the literature.
Front. Med. 10:1186494.
doi: 10.3389/fmed.2023.1186494

COPYRIGHT
© 2023 Frontiers Production Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted which
does not comply with these terms.

Erratum: Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

purpura, thrombotic thrombocytopenic, ADAMTS13, mRNA SARS-CoV-2 vaccine, COVID-19 vaccine

An Erratum on

[Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature](#)

by Buetler, V. A., Agbariah, N., Schild, D. P., Liechti, F. D., Wieland, A., Andina, N., Hammann, F., and Kremer Hovinga, J. A. (2022). *Front. Med.* 9:890661. doi: 10.3389/fmed.2022.890661

An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Bern.”

The original article has been updated.